What question did this study set out to answer?

The aim is to examine the complexities of managing ophthalmic inflammation and to review emerging therapeutic strategies.

April 14, 2026

Ophthalmic Inflammation: Evolving Strategies and Therapeutic Hurdles

Puntos clave

The aim is to examine the complexities of managing ophthalmic inflammation and to review emerging therapeutic strategies.
Comprehensive analysis of ocular inflammation types including uveitis, scleritis, keratitis, and conjunctivitis.
Evaluation of immune mechanisms and diagnostic tools for identifying causes of inflammation.
Discussion of advancements in therapeutic strategies including gene therapy and nanotechnology.
Identified significant challenges in managing treatment side effects and disease relapse.
Highlighted the promise of novel therapies like biologics and gene therapy for improved outcomes.
Emphasized the need for personalized treatment approaches to enhance patient safety and effectiveness.

Resumen

Ophthalmic inflammation includes a variety of eye disorders that can severely impact vision and overall quality of life. Despite substantial progress in diagnostic modalities and the development of targeted therapies, the effective management of ophthalmic inflammation continues to pose significant challenges. These challenges arise from the intricate interplay of immune pathways, heterogeneity of clinical manifestations, and the high propensity for treatment-associated adverse effects. Traditional therapeutic approaches, including corticosteroids and systemic immunosuppressants, though initially efficacious, are frequently limited by complications and disease relapse. Recent innovations such as gene therapy, biologics, and nanotechnology-based drug-delivery platforms present promising opportunities for more selective and safer interventions. Nevertheless, successful clinical translation demands individualized treatment paradigms, durable therapeutic outcomes, and an advanced understanding of ocular immunopathogenesis. This review comprehensively explores the pathophysiological basis of ocular inflammation, including uveitis, scleritis, keratitis, and conjunctivitis, along with their epidemiology and global impact. It also highlights key immune mechanisms, including Th1/Th17 pathways, cytokines, and oxidative stress, that drive tissue damage and break ocular immune privilege. Furthermore, diagnostic approaches that include clinical assessment, imaging tools such as OCT and angiography, laboratory tests including serology, PCR, and biomarkers that help differentiate between infectious and non-infectious causes are explored. The emerging therapeutic strategies, evolving technological platforms, and underscoring the imperative for multitarget approaches to overcome the limitations of current interventions are also discussed. In addition, the study emphasizes evidence-based recommendations by highlighting recent advances in drug delivery and immune modulation to improve patient safety, optimize visual outcomes, and guide future research directions.

Preguntar a la IA

Me gusta

Guardar